Shots:

• BridgeBio to receive ~$2.45B+ including ~$100M in up front- regulatory and commercial milestones along with royalties on net sales of Infigratinib from Helsinn Group. The agreement is expected to close in Q2’21
• Helsinn to co-commercialize infigratinib in oncology and other indications except for skeletal dysplasia indications in the US and will equally share profits and losses. Additionally- BridgeBio will retain all rights in skeletal dysplasia including achondroplasia
• Helsinn will lead and have exclusive commercialization rights for infigratinib in non-skeletal dysplasia indications outside the US excluding China- Hong Kong- and Macau. Additionally- the FDA is reviewing an NDA for infigratinib to treat patients with previously treated- FGFR-mutant cholangiocarcinoma

  Ref: BridgeBio | Image: PRNewswire